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Hippocampal dysfunctions may play an important role in the non-motor aspects of 
Parkinson’s disease (PD), including depressive and cognitive symptoms. Fine structural 
alterations of the hippocampus and their relationship with symptoms and medication 
effects are unknown in newly diagnosed PD. We measured the volume of hippocampal 
subfields in 35 drug-naïve, newly diagnosed PD patients without cognitive impairment 
and 30 matched healthy control individuals. Assessments were performed when the 
patients did not receive medications and after a 24-week period of l-DOPA treatment. 
We obtained a T1-weighted 3D magnetization-prepared rapid acquisition gradient 
echo image at each assessment. FreeSurfer v6.0 was used for image analysis. Results 
revealed a selectively decreased CA2–CA3 volume in non-medicated PD patients, which 
was normalized after the 24-week treatment period. Higher depressive symptoms were 
associated with smaller CA2–CA3 volumes. These results indicate that the CA2–CA3 
subfield is structurally affected in the earliest stage of PD in the absence of cognitive 
impairment. This structural anomaly, normalized by l-DOPA, is related to depressive 
non-motor symptoms.
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inTrODUcTiOn
Recently, the structure and function of the hippocampal formation received widespread attention 
in Parkinson’s disease (PD) as a potential neural substrate of cognitive dysfunctions and other 
non-motor symptoms (e.g., depression, impulse control disorders, and hyposmia) (1). The hip-
pocampal complex forms dense connections with the neocortex and subcortical structures, receives 
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dopaminergic innervation from mesencephalic centers, and par-
ticipates in learning, memory, multimodal sensory integration, 
spatial navigation, and emotion regulation (2, 3). From a structural 
point of view, the hippocampus comprises several histologically 
distinguishable modules, such as the Cornu Ammonis regions, 
dentate gyrus (DG), presubiculum, and subiculum, which may 
be specifically affected in different diseases (2, 3).
Although not without controversy and technical limitations 
(4), recent advances in in vivo hippocampal subfield measure-
ments provide a unique opportunity to gain insight into hidden 
structural alterations in brain diseases. However, currently, there 
is no consensus about the most appropriate imaging method 
and analytical software for such measurements. FreeSurfer, 
a publicly available software (5), is suitable for the automated 
segmentation of the hippocampus in large and heterogeneous 
clinical samples. In several studies, FreeSurfer has been success-
fully used to find relationships between clinical features and 
hippocampal structure in various neurological and psychiatric 
illnesses (6–10).
Although several studies have demonstrated hippocampal 
atrophy even in non-demented PD patients (11–15), the results 
are still controversial (16–18). Pereira et  al. (19) demonstrated 
smaller CA2–CA3 and CA4–DG subfields in PD patients relative 
to matched healthy control individuals, which were linked to less 
efficient learning performances. In the same sample, reduced 
subiculum volume was related to visual hallucinations (19). Beyer 
et al. (20) found a significant association between deficient recall 
on a verbal memory task and atrophy in CA1, CA3, and subicu-
lum in drug-naïve, newly diagnosed PD patients. Although the 
study of Beyer et al. (20) reported results from a large sample of 
newly diagnosed PD patients, matched control subjects were not 
included, and the effect of medications was not explored (20). 
Structural abnormalities in the hippocampus may be associated 
with mild cognitive impairment (MCI) (21) and depression (22) 
in PD.
An increasing number of studies indicate that dopaminergic 
medications modulate structural and functional plasticity in 
the hippocampus, including long-term synaptic depression and 
potentiation, subunit composition of glutamate receptors, and 
neurogenesis in the DG (23–25). Despite the fact that these find-
ings are important for acquiring an understanding of non-motor 
symptoms and the effects of dopaminergic medications in PD, the 
influence of commonly used antiparkinsonian agents on human 
hippocampal structure has not been elucidated yet.
Therefore, the current study had the following aims: (a) to 
explore possible structural differences in hippocampal subfields 
between drug-naïve, newly diagnosed PD patients without cogni-
tive deficits and matched healthy control subjects; (b) to investi-
gate the relationship between hippocampal structural alterations 
and clinical characteristics with a special reference to depressive 
symptoms; and (c) to conduct a longitudinal assessment focusing 
on the effect of l-DOPA on hippocampal subfield structure.
Our hypotheses were as follows: (a) drug-naïve, newly 
diagnosed PD patients show reduced CA2–CA3 and CA4–DG 
volumes (19). (b) Volume reductions are associated with depres-
sive symptoms (22). (c) l-DOPA medication is associated with 
increased hippocampal subfield volumes (25).
MaTerials anD MeThODs
Participants
Thirty-five patients with PD and 30 healthy subjects matched for 
age, gender, education, socioeconomic status, IQ, and body mass 
index were enrolled. The study was conducted at the National 
Institute of Psychiatry and Addiction, Budapest, Hungary. We 
contacted eight outpatient centers specialized in the diagnosis 
and treatment of PD. The clinical diagnosis was made, and the 
scales were administered by trained neurologists and psychia-
trists. All patients meet the UK Parkinson’s Disease Society Brain 
Bank clinical diagnostic criteria (26).
We used the following scales for the clinical and demographic 
characterization of the patients: Hoehn–Yahr scale (27) (number 
of patients in each stage: 1:7, 1.5:5, 2:20, 2.5:3), Unified Parkinson’s 
Disease Rating Scale (UPDRS) (28), Hamilton Depression Rating 
Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A) (29), 
Hollingshead Four-Factor Index for socioeconomic status (30), 
and the Wechsler Adult Intelligence Scale (WAIS-R) for general 
intellectual functions (31). Impulsive–compulsive spectrum 
behavior was evaluated according to the criteria of Voon and Fox 
(32). MCI was excluded based on the criteria of the Movement 
Disorder Society Task Force guideline (33). Participants received 
the Montreal Cognitive Assessment, Rey’s Auditory Verbal 
Learning Test, semantic/phonological fluency, Visual Form 
Discrimination Test, and the Benton Facial Recognition Test (19, 
34). General exclusion criteria included a history of neurological 
and psychiatric disorders including MCI and impulsive–compul-
sive symptoms, diabetes mellitus, hypertension, and smoking. 
The participants did not lose or gain more than 2% of their body 
weight during the study period.
After the baseline testing in non-medicated state, PD patients 
started l-DOPA therapy for 24 weeks (mean dose at follow-up: 
450.0  mg/day, range: 300–600  mg/day). The selection of the 
appropriate dose of l-DOPA medication was at the discretion 
of the treating clinician. After the 24-week period, patients and 
controls were re-evaluated. The clinical and demographic data are 
summarized in Tables 1 and 2.
structural Magnetic resonance imaging
During the acquisition and processing of images, we followed the 
protocol of Marizzoni et al. (35), which provided evidence for the 
longitudinal reproducibility of automated hippocampal subfield 
measurements (35). The protocol included a structural T1 volume 
at each assessment [Philips Achieva 3 T scanner, magnetization-
prepared rapid acquisition gradient echo, 3D sagittal acquisition, 
square field of view = 256 mm, acquisition matrix: 256 × 256, voxel 
size: 1 mm × 1 mm × 1 mm, TI = 900 ms, TE (shortest) = 3.16 ms, 
flip angle: 9 degrees, no fat suppression, full k space, no averages, 
acquisition time: 6 min and 50 s, acceleration factor: 2].
For image processing, we used the neuGRID platform and the 
longitudinal pipeline of FreeSurfer v6.0 with the “hipposubfields” 
flag1 (36). After a within-session averaging of T1-weighted images, 
we performed an automatic hippocampal subfield segmentation 
1 http://freesurfer.net.
TaBle 2 | clinical measures in Parkinson’s patients.
Baseline Follow-up t p
UPDRS total 38.3 (5.1) 33.5 (5.7) 3.46 0.001
UPDRS motor 25.4 (3.8) 20.7 (4.4) 3.95 0.0003
HAM-D 11.6 (7.0) 7.6 (4.0) 2.45 0.02
HAM-A 3.5 (2.7) 4.0 (3.4) −0.50 0.62
Data are mean (SD). Results from the baseline, non-medicated condition were 
compared with those from the follow-up, medicated condition by two-tailed t-tests.
UPDRS, Unified Parkinson’s Disease Rating Scale; HAM-D, Hamilton Depression 
Rating Scale; HAM-A, Hamilton Anxiety Rating Scale.
TaBle 1 | Demographic and neuropsychological characteristics of the 
participants.
Parkinson’s patients 
(n = 35)
control subjects 
(n = 30)
Age (years) 51.9 (7.2) 51.3 (6.4)
Gender (male/female) 21/14 20/10
Education (years) 14.5 (3.8) 14.1 (3.9)
Socioeconomic status 37.7 (9.1) 37.5 (10.6)
BMI (kg/m2) 24.7 (7.6) 24.9 (8.1)
IQ 106.8 (11.0) 104.6 (11.0)
Montreal Cognitive Assessment 29.0 (3.2) 28.7 (2.9)
RAVLT—learning 42.8 (7.5) 41.8 (7.9)
RAVLT—recall 9.8 (2.7) 9.4 (2.5)
RAVLT—recognition 15.9 (2.1) 15.7 (1.9)
Semantic fluency 20.6 (4.4) 20.1 (5.0)
Phonological fluency 13.8 (4.2) 14.0 (4.5)
Visual Form Discrimination Test 31.0 (1.6) 31.2 (1.7)
Benton Facial Recognition Test 49.8 (2.7) 49.5 (2.6)
Data are mean (SD) with the exception of gender distribution. There were no significant 
differences between Parkinson’s patients and healthy control participants (ps > 0.5).
RAVLT, Rey’s Auditory Verbal Learning Test; BMI, body mass index.
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(5). Image processing included the following steps: (1) correc-
tion for within-subject head motion; (2) removal of non-brain 
tissue using a hybrid watershed/surface deformation algorithm; 
(3) affine registration to Talairach space; and (4) segmentation 
of cortical and subcortical structures with a Probabilistic Brain 
Atlas (37).
The FreeSurfer module for hippocampal segmentation is 
based on a Bayesian model with Markov random field priors (5). 
In FreeSurfer v6.0, a newly developed version of the hippocampal 
segmentation tool has been implemented (38). Briefly, ultra-
high-resolution (0.13 mm) ex vivo MRI scans from 15 autopsy 
samples were manually segmented, together with a delineation of 
neighboring structures from in vivo, T1-weighted images (1 mm 
resolution). The manual labels from the ex vivo and in vivo scans 
were integrated to establish an atlas of the hippocampal formation 
with a new Bayesian inference algorithm to detect local variations 
in MRI contrast. This new method has several advantages over 
previous versions of the FreeSurfer hippocampal segmentation 
module (38, 39).
We segmented and measured the volume of the following sub-
fields: CA1, CA2–CA3, CA4–DG, subiculum, and presubiculum 
(Figure 1). Hippocampal subfield volumes were adjusted by the 
total intracranial volume (40). The fimbria and the hippocampal 
fissure were not included in the analysis because the segmenta-
tion of these small structures is inaccurate, and their longitudinal 
reproducibility is insufficient (9, 35). We averaged the volumetric 
data across hemispheres because we did not establish a hypothesis 
regarding laterality (volumetric differences between the left and 
right hippocampus), and our exploratory analyses did not indi-
cate significant differences between left and right hippocampal 
subfields in PD. In this way, we could reduce the number of vari-
ables in our relatively small sample.
In 15 healthy control individuals, we validated the FreeSurfer 
hippocampal subfield measurement against the widely used 
AdaBoost machine-learning segmentation method (20, 41, 42). 
AdaBoost employs statistical rules for subfield segmentation 
based on numerous voxel-specific features (e.g., image gradients, 
local curvatures, classification of gray or white matter, and 
stereotaxic position of the hippocampus) using a training dataset. 
The AdaBoost algorithm labels each voxel in MRI images to be 
segmented and delineates hippocampal subfields. AdaBoost 
is able to detect hippocampal atrophy at least as effectively as 
manual segmentation and FreeSurfer (43). Intraclass correlation 
coefficients (ICCs) between AdaBoost and FreeSurfer delinea-
tions were calculated using a two-way random ANOVA model 
with absolute agreement (44). We found good to excellent ICCs 
according to the definition of Cicchetti (45) (CA1: 0.68; CA2–
CA3: 0.76; CA4–DG: 0.79; subiculum: 0.67; presubiculum: 0.74).
Finally, we evaluated the test–retest reliability of automated 
FreeSurfer measures by calculating Pearson’s correlation coef-
ficients between subfield values measured at baseline and 
follow-up. We found high correlation coefficients indicating good 
test–retest reliabilities (CA1: 0.82; CA2–CA3: 0.81; CA4–DG: 
0.80; subiculum: 0.84; presubiculum: 0.84).
Voxel-Based Morphometry (VBM)
A whole-brain VBM was performed to detect possible gray 
matter differences between PD patients and controls. We used 
the VBM8 toolbox of SPM82 and the Diffeomorphic Anatomical 
Registration Through Exponentiated Lie Algebra toolbox under 
a MATLAB 7.14 platform (MathWorks, Natick, MA, USA) 
(46, 47). Image analysis involved the following steps: (1) 
segmentation of the raw MRI images in native space into gray 
matter, white matter, and cerebrospinal fluid; (2) normalization of 
images to gray matter and white matter templates in stereotactic 
space; (3) automatic segmentation of normalized images; and (4) 
smoothing (8-mm, full-width, half-maximum Gaussian kernel).
We applied general linear model for the statistical analysis of 
VBM data (voxel-wise estimation of the local amount of gray mat-
ter) with total gray matter volume as a covariate. The voxel-wise 
threshold was p < 0.001, uncorrected (extent threshold: K = 20 
voxels). The extent threshold was determined with AlphaSim 
employing Monte Carlo simulations (number of iterations: 1,000, 
alpha-level: 0.05) (48).
statistical analysis of hippocampal 
subfields and clinical Measures
We used STATISTICA 12 software (StatSoft, Tulsa) for data 
analysis. Kolmogorov–Smirnov tests and Levene’s tests did not 
2 http://www.fil.ion.ucl.ac.uk/spm.
TaBle 3 | hippocampal subfield volumes (mm3).
subfields Parkinson’s disease 
(n = 35)
control subjects 
(n = 30)
effect 
size
Mean sD 95% ci Mean sD 95% ci d
Baseline
CA1 342.3 69.3 318.5–
366.1
350.6 70.8 324.1–
377.0
0.12
CA2–CA3* 742.3 97.9 708.7–
776.0
831.6 88.6 798.5–
864.7
0.87
CA4–DG 543.5 73.5 518.2–
568.7
567.8 66.1 543.2–
592.5
0.34
Subiculum 589.3 75.2 563.5–
615.1
574.6 90.9 540.7–
608.6
0.18
Presubiculum 388.5 87.8 358.3–
418.7
415.2 77.8 386.2–
444.3
0.32
Follow-up
CA1 345.0 71.6 320.4–
369.6
355.6 73.0 328.4–
382.9
0.15
CA2–CA3 851.7 83.4 823.1–
880.3
838.6 88.0 805.7–
871.5
0.15
CA4–DG 564.3 80.8 536.5–
592.0
569.3 60.2 546.8–
591.8
0.06
Subiculum 572.8 76.0 546.7–
599.0
576.2 98.1 539.6–
612.9
0.05
Presubiculum 386.0 91.0 354.8–
417.3
418.5 79.6 388.7–
448.2
0.38
At baseline, Parkinson’s patients did not receive medications. Follow-up measurements 
were conducted after 24 weeks of l-DOPA treatment in the patient group. Healthy 
control subjects did not receive any medications. Hippocampal subfield volumes (mm3) 
from the patients and control subjects were compared with analysis of variance and 
Tukey honestly significant difference tests (*p < 0.0001). Effect size values (Cohen’s d) 
were also calculated.
95% CI, 95% confidence interval; CA, Cornu Ammonis; DG, dentate gyrus.
FigUre 1 | coronal (a) and sagittal (B) T1-weighted images from the average output of Freesurfer hippocampal segmentation from healthy 
individuals.
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indicate significant deviations from normal distribution and 
inhomogeneity of variance, respectively (ps > 0.5). Therefore, we 
performed an ANOVA on hippocampal subfield volumes. The 
between-subjects factor was the experimental group (PD patients 
vs. control individuals). The within-subject factors were assess-
ment session (baseline, non-medicated state in PD vs. follow-up, 
PD patients on l-DOPA) and hippocampal subfields. Tukey 
honestly significant difference (HSD) tests for unequal samples 
were used for post hoc comparisons. Cohen’s effects size values 
(d) were also calculated. Demographic data were compared with 
two-tailed Student’s t-tests. Pearson’s product moment partial 
correlations were calculated between scales assessing depression 
(HAM-D), anxiety (HAM-A), PD symptoms (UPDRS total and 
motor subscales), and hippocampal subfield volumes. Fisher r-to-
z transformation was used to compare correlation coefficients. 
The level of statistical significance was set at alpha <0.05. We 
used the false discovery rate (FDR) method for the correction of 
multiple comparisons.
resUlTs
hippocampal subfields
Figure  1 depicts the hippocampal segmentation results. 
Hippocampal subfield volumes are shown in Table 3. Analysis 
of variance (ANOVA) indicated a significant difference between 
PD patients and control subjects (a main effect of experimental 
group) [F(1,63) = 4.01, p < 0.05, η2 = 0.06]. Furthermore, there 
was a significant main effect of assessment session (baseline 
vs. follow-up) [F(1,43) = 30.54, p < 0.001, η2 = 0.33] and hip-
pocampal subfields [F(4,252) = 384.51, p < 0.001, η2 = 0.86]. 
We found two-way interactions between group and assessment 
session [F(1,63) =  15.91, p <  0.001, η2 =  0.20], and assess-
ment session and hippocampal subfields [F(4,252) =  15.69, 
p < 0.001, η2 = 0.20]. Most importantly, there was a three-way 
interaction among experimental group, assessment session, 
and hippocampal subfields [F(4,252)  =  13.59, p  <  0.001, 
η2 = 0.18].
Tukey HSD tests conducted on the three-way interaction 
indicated that the baseline CA2–CA3 volumes were significantly 
smaller in non-medicated PD patients as compared to the control 
group (p < 0.0001). No between-group differences were found for 
other hippocampal subfields in the baseline condition (ps > 0.7) 
(Table 3). At the follow-up assessment, we did not find significant 
differences between PD patients and healthy controls (ps > 0.7) 
(Table 3).
In patients with PD, we observed a significant increase in 
CA2–CA3 volumes during the follow-up period (non-medicated 
FigUre 2 | correlations between depressive symptoms and ca2–ca3 volumes before (non-medicated, left panel) and after l-DOPa medication 
(medicated, right panel).
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vs. medicated state, p  <  0.001). There were no significant 
changes in the remaining hippocampal subfields (p > 0.5).
correlations between hippocampal 
subfield Volumes and clinical symptoms
We calculated partial correlations, corrected for age, gender, and 
education, between hippocampal subfields and clinical symptoms 
(UPDRS total and motor symptoms, HAM-D, and HAM-A). At 
both baseline and follow-up assessments, more severe depressive 
symptoms (HAM-D) were associated with smaller CA2–CA3 vol-
umes (rbaseline = −0.74 and rfollow-up = −0.37, ps < 0.05) (Figure 2), 
although the correlation coefficient at follow-up was significantly 
smaller than that at baseline (Z = −2.25, p = 0.02).
A similar relationship was observed for anxiety, but it was sig-
nificant only at the baseline assessment (rbaseline = −0.47, p < 0.05). 
There were no significant correlations for other hippocampal 
subfields and UPDRS/HAM-D/HAM-A scores (−0.3 < rs < 0.3, 
ps > 0.05). When FDR corrections were used, only the relation-
ship between baseline depressive symptoms and CA2–CA3 
volume retained significance.
Voxel-Based Morphometry
There was no significant difference in gray matter volume between 
PD patients and control subjects even at the screening threshold 
(p < 0.001, uncorrected).
DiscUssiOn
The findings of the present study indicate that the CA2–CA3 
subfield of the hippocampal formation is significantly reduced 
even in the earliest stage of clinically diagnosed PD. Moreover, 
in the initial period of l-DOPA treatment, this volumetric altera-
tion, associated with depressive symptoms, shows improvement.
The results are in accordance with neuropathological studies 
indicating a pronounced neurodegeneration in the CA2 field 
in PD (49), although we were only able to measure a collapsed 
CA2–CA3 field. Pereira et al. (19) also demonstrated a decreased 
volume in CA2–CA3, but in their study, a smaller CA4–DG 
volume was also observed in PD patients. We did not detect sig-
nificant atrophy in CA4–DG, probably because we investigated 
newly diagnosed, early-stage PD patients.
The CA2–CA3 subfield is critical in the formation of new 
memories (50, 51). Moreover, CA2 may be a pivotal interface 
between brain regions responsible for emotional processing and 
higher level cognitive functions (52). Considering its role in 
social memory, unique cytoarchitectonic properties, and neuro-
modulation, CA2 may be a key target for the treatment of social 
and emotional dysfunctions in various neuropsychiatric illnesses 
(52). In line with these findings, we demonstrated that the CA2–
CA3 region may be critical in the emergence of early affective 
symptoms in PD: at baseline, more severe depressive symptoms 
were associated with smaller CA2–CA3 volumes. At the second 
assessment, when PD patients received l-DOPA, depressive 
symptoms were improved, and their correlation with the CA2–
CA3 volume was less pronounced. This observation provides 
insight into the neuronal correlates of the early antidepressive 
effects of l-DOPA (53). This finding is clinically relevant because 
a significant proportion of PD patients suffer from depression 
(pooled prevalence: 22.9%) (54), which markedly affects quality 
of life (55).
It is worth noting that several studies revealed a widespread 
hippocampal volume loss in major depressive disorder instead 
of a circumscribed deficit in certain subfields (3). A possible 
explanation may be that in our PD patients, depressive symptoms 
were not as severe as in individuals with a clinical diagnosis of 
major depressive disorder, or depressive symptoms have distinct 
mechanisms in major depressive disorder and PD. In patients 
with PD and comorbid depression, several studies have demon-
strated widespread structural alterations in prefrontal and limbic 
regions, although some research groups failed to detect significant 
differences between depressed and non-depressed PD patients 
(56). Others emphasized the special role of the limbic thalamus 
6Györfi et al. Hippocampal Subfields in PD
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(57). van Mierlo et  al. (22) demonstrated a complex relation-
ship between depression and brain structure in PD: depression 
scores negatively correlated with bilateral hippocampus and right 
amygdala volume and positively with anterior cingulate cortex 
volume. It has been suggested that depression and neurodegen-
erative processes may share several pathophysiological features, 
including decreased production of neurotrophic factors, reduced 
neurogenesis, abnormal synaptic plasticity, and enhanced neuro-
inflammation in the hippocampus (58).
We found that a 24-week period of l-DOPA treatment 
restored CA2–CA3 volume in PD patients. This suggests that 
during the initial stage of PD, dopaminergic medications ame-
liorate hippocampal structural changes. The mechanism of this 
effect is not exactly understood. Chiu et  al. (25) demonstrated 
that l-DOPA is able to restore neurogenesis in the DG of mice 
with bilateral intra-nigral 6-hydroxy-dopamine lesion, together 
with the improvement of Parkinson-like non-motor behavior. 
In addition to specific influences on neurogenesis, dopamine 
is able to modify the synthesis of neurotrophic factors exerting 
effects on neuronal structure and function (59) and modulating 
inflammatory responses (60). α-Synuclein triggered microglial 
activation, and neuroinflammation may be especially relevant in 
the hippocampus of PD patients (61).
It is essential to consider that non-specific factors, such as 
overall body weight, nutritional status, local water content, and 
astroglia activation, may account for changes in brain volume 
(62–64). To tackle these issues, we controlled body weight and 
asked the participants not to change their dietary habits and 
physical activity during the study. Moreover, it is not likely 
that non-specific factors may selectively affect the CA2–CA3 
region.
We also conducted a whole-brain VBM to elucidate a possible 
extra-hippocampal volume loss. We did not find any evidence 
for extra-hippocampal structural alterations in newly diagnosed 
PD patients with spared cognitive functions relative to control 
participants, which is consistent with previous findings (65, 66). 
Two recent meta-analyses of VBM studies in PD failed to prove 
hippocampal gray matter reduction (67, 68), whereas a marked 
medial temporal lobe atrophy was reported in PD patients with 
dementia (69). The fact that VBM did not reveal hippocampal 
volume loss in our patients is neither surprising nor contradic-
tory. Whole-brain VBM without region of interest analysis using 
hippocampal masks fails to detect even larger hippocampal 
atrophy than that found in our study (70).
Our study is not without limitations. First, the validity of 
FreeSurfer hippocampal segmentation has been questioned (4). 
It seems that the discrepancy between FreeSurfer and manual 
methods is the largest for CA1 (71, 72). Specifically, by comparing 
manual segmentation and FreeSurfer, de Flores et al. (71) reported 
low to moderate ICCs (0.31–0.74) for subiculum, other subfields, 
and whole hippocampus, but for CA1, the correlation was very 
small (0.02). The CA2–CA3 and CA4–DG subfields could not 
be discriminated during manual segmentation, and therefore, the 
authors reported these subfields together. They concluded that 
“the correlations between FreeSurfer and manual measurements 
were reasonable for the SUB (subiculum) and CA2–3-4-DG 
subfields pooled together” (p. 472) (71).
Manual segmentation and FreeSurfer can similarly detect 
volumetric differences in CA2–CA3 in clinical and healthy 
populations (72). The advantage of FreeSurfer is that it allows 
replicability across different scanners, analytical softwares, and 
experimental samples in longitudinal studies (35). Another 
advantage is that FreeSurfer does not require high-resolution 
T2-weighted scans with hippocampal focus, which is sensitive for 
motion and other types of MRI artifacts (72). Finally, in a group 
of healthy individuals, we found convincing correlations between 
FreeSurfer measures and data obtained from the AdaBoost 
machine-learning segmentation protocol, which is frequently 
used in clinical populations (20).
The second limitation is that our study did not include a clinical 
group receiving placebo. We have no information about spontane-
ous changes in hippocampal structure during the early course of 
PD. However, it is unlikely that the CA2–CA3 region might undergo 
a spontaneous volume expansion. A truly critical question for 
future studies is when and why medication-related volume com-
pensation is lost and it eventually turns into progressive atrophy.
The third main limitation is that the sample size was small. 
However, the obtained significance level for CA2–CA3 was 
convincing with a Cohen’s effect size larger than 0.8 (Table 3). 
The critical three-way interaction in the ANOVA was also highly 
significant with a large effect size according to Cohen’s criteria 
(0.18) (73). It is important to note that it is difficult to recruit de 
novo, non-medicated PD patients because general practitioners 
and other specialists often start various medications (e.g., antide-
pressants) before the final diagnosis of PD.
In conclusion, newly diagnosed PD patients exhibit a selective 
reduction of the CA2–CA3 subfield of the hippocampus, which 
is ameliorated by l-DOPA during the initial phase of the disease. 
These findings should be interpreted taking into account the 
small sample size and the lack of a placebo group. Future studies 
should assess the long-term effect of dopaminergic medications 
in relation to progressive brain volume loss and non-motor 
symptoms of PD.
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